奥美拉唑联合硫糖铝持续口服预防乙型肝炎肝硬化患者上消化道再出血的疗效观察

Omeprazole combined with sucralfate on the prevention of upper gastrointestinal rebleeding in the cirrhosis with hepatitis B

目的观察奥美拉唑联合硫糖铝持续口服预防乙型肝炎肝硬化患者上消化道再出血的临床疗效。方法将62例首次发生上消化道出血的乙型肝炎肝硬化患者分为预防组和对照组,预防组32例用奥美拉唑和硫糖铝持续口服,对照组30例未持续用药预防,时间为12个月。两组分别统计12个月内再出血总人次、住院总人次、再出血病例数和住院病例数。结果 12个月内预防组再出血总人次(平均人次)和住院总人次(平均人次)均明显低于对照组;预防组再出血病例数和住院病例数也明显低于对照组(P<0.001)。结论奥美拉唑联合硫糖铝持续口服预防乙型肝炎肝硬化患者上消化道再出血有较好的效果。

Objective To study the effect of continuous treatment with oral omeprazole combined with sucralfate in preventing upper gastrointestinal rebleeding in liver cirrhosis with hepatitis B. Methods Sixty two patients who had upper gastrointestinal hemorrhage were divided into prevention group and control group. Thirty two patients of prevention group took oral omeprazole combined with sucralfate for 12 months, while the patients in control group didn＇ t take the medicine. The number of patients who had upper gastrointestinal hemorrhage and rebleeding, and the number of inpatients in the two groups were compared. Results The number of patients who had reoccurence of upper gastrointestinal hemorrhage and the number of inpatients in prevention group were lower than that of in control group after 12 months（ P 〈 0. 001 ）. Conclusion Omeprazole combined with sucralfate is an effective method to prevent upper gastrointestinal rebleeding in liver cirrhosis with hepatitis B.